Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
Stanford University
Stanford University
Pfizer
M.D. Anderson Cancer Center
Erasca, Inc.
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Jonsson Comprehensive Cancer Center
Pfizer
Solve Therapeutics
Memorial Sloan Kettering Cancer Center
M.D. Anderson Cancer Center
UNC Lineberger Comprehensive Cancer Center
Actym Therapeutics, Inc.
M.D. Anderson Cancer Center
Memorial Sloan Kettering Cancer Center
National Taiwan University Hospital
Ikena Oncology
Memorial Sloan Kettering Cancer Center
Eli Lilly and Company
Jonsson Comprehensive Cancer Center
Sichuan Enray Pharmaceutical Sciences Company
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Eli Lilly and Company
Columbia University
Thomas Jefferson University
Osaka University
Theratechnologies
The First Affiliated Hospital of Xiamen University
Sotio Biotech Inc.
University Medical Center Groningen
ABM Therapeutics Corporation
National Cancer Institute (NCI)
Memorial Sloan Kettering Cancer Center
Roswell Park Cancer Institute
MacroGenics
Fore Biotherapeutics
Celgene
Celgene
University of Colorado, Denver
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
AHS Cancer Control Alberta
Celldex Therapeutics
SWOG Cancer Research Network
Memorial Sloan Kettering Cancer Center
University of Washington
Valerio Therapeutics
Valerio Therapeutics
University of Chicago
National Cancer Institute (NCI)
Calando Pharmaceuticals
National Cancer Institute (NCI)